WebBIVV001 is a fusion protein consisting of VWF-D’D3 domain fused to rFVIII via immunoglobulin-G1 Fc domains and 2 XTEN polypeptides (Amunix Pharmaceuticals, … WebMar 11, 2024 · These findings showed that BIVV001 could provide a high level of sustained factor VIII activity in patients with severe hemophilia A. Overall, single-dose BIVV001 …
BIVV001 Fusion Protein as Factor VIII Replacement …
WebJul 21, 2024 · Sanofi and Swedish Orphan Biovitrum ABÂ presented for the first time today, in a late-breaking session at the 30 th International Society on Thrombosis and Haemostasis (ISTH) Congress, positive results from the XTEND-1 pivotal Phase 3 study evaluating the safety, efficacy and pharmacokinetics of efanesoctocog alfa (BIVV001), an … WebBIVV001 is a fusion protein consisting of VWF-D’D3 domain fused to rFVIII via immunoglobulin-G1 Fc domains and 2 XTEN polypeptides (Amunix Pharmaceuticals, Inc.). 23 BIVV001 had an increase in FVIII half-life ranging from 25–31 hours and 33–34 hours in mice and monkeys, respectively. 23 In early phase trials in men with severe hemophilia ... hotel ibis brussels expo atomium
Developing BIVV001, a new class of factor VIII replacement for ...
WebJan 9, 2024 · by Alejandra Viviescas, PhD January 9, 2024. A single dose of BIVV001 significantly increased levels of factor VIII for a week in the blood of people with severe hemophilia A, according to early results of a Phase 1/2a study. The treatment increased the half-life of factor VIII to 44 hours and showed no side effects or development of inhibitors. What is Altuviiio for hemophilia? Altuviiio (efanesoctocog alfa), previously known as BIVV001, is an approved long-lasting factor VIII (FVIII) replacement therapy for children and adults with hemophilia A.It is indicated as a prophylactic or preventive therapy to lower the frequency of bleeding episodes, and also can … See more Efanesoctocog alfa is based on Fc fusion technology, and is made by adding a region of a blood-clotting protein called von Willebrand factor (VWF) and a polypeptide … See more Sanofi and Sofi announced plans to begin filing applications to regulatory agencies in 2024 requesting that efanesoctocog alfa be approved to treat … See more In preclinical studies, the pharmacological properties of efanesoctocog alfa were found to be similar to those of recombinant FVIII (rFVIII). The … See more An open-label (no placebo group), dose-escalation Phase 1/2a study, called EXTEN-A (NCT03205163), investigated the safety, tolerability, and pharmacokinetics … See more WebFeb 19, 2024 · Replacement therapies for hemophilia A work by providing patients with a man-made version of FVIII, the clotting protein they are missing. Formerly known as BIVV001, efanesoctocog alfa is a new form of FVIII replacement therapy that is being co-developed by Bioverativ, a Sanofi company, and Sobi. pub jobs portsmouth